High-Throughput Immunomodulator Screening Reveals Subtype-Specific Responses in Low-Abundance Immune Cell Populations Using Scalable scRNA-seq 2260031

S Sarah Schroeder O Olivia Kaplan (Parse Biosciences) V Vuong Tran (Parse Biosciences) S Simone Marrujo (Parse Biosciences) A Alec Salvino (Parse Biosciences) A Ajay Sapre (Parse Biosciences) I Ian Dowsett (Parse Biosciences) Z Zeynep Sayar (Parse Biosciences) A Alex Koriath (Parse Biosciences) A Alex Sova (Parse Biosciences) J Jason Siputro (Parse Biosciences) G Gary Geiss (Parse Biosciences) C Charles Roco (Parse Biosciences) A Alex Rosenberg (Department of Anaesthesia and Critical Care, Royal Brompton & Harefield Hospitals, Guy’s and St Thomas’ National Health Service Foundation Trust, London, United Kingdom (A.R., C.V.).)

Abstract

Abstract Introduction Understanding immune cell variability including rare populations is essential for dissecting inflammatory mechanisms and therapeutic response. However, functional screening of immunomodulators is often limited by precious sample availability and cell loss during processing. Methods We present a fixation-compatible combinatorial barcoding workflow optimized for low-input immune samples (< 20,000 PBMCs), enabling high-resolution profiling of rare subsets such as classical monocytes, regulatory T cells, and B-cell subtypes. This approach supports 96-condition parallel perturbation while preserving transcriptomic integrity and subtype recovery (>65% retention), even in fragile or low-abundance populations. Results In a screen of 88 immunomodulatory compounds in cultured PBMCs, including PDE4 inhibitors and glucocorticoids, we identified both drastic and subtle shifts in gene expression within classical monocytes, alongside pathway-specific perturbations in B and T cell compartments. Notably, compounds targeting the same pathway elicited concordant transcriptional programs, enabling comparative pharmacodynamic insights at single cell resolution. Conclusion This scalable low-input single-cell approach enables detailed investigation of immune cell behavior under perturbation, capturing both robust and subtle transcriptional responses across rare and abundant PBMC subsets. By accommodating limited sample availability, it supports exploration of how immunomodulators influence cell states, lineage stability, and inflammatory programs at high resolution. Such screens enable efficient discoveries of drug efficacy and detection of secondary effects, offering a powerful experimental framework for uncovering immune mechanisms, comparative pathway responses, and context-dependent variability within complex immune systems. Funding Source n/a Topic Categories Technological Innovations in Immunology (TECH)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (14)

S

Sarah Schroeder

O

Olivia Kaplan

Parse Biosciences

V

Vuong Tran

Parse Biosciences

S

Simone Marrujo

Parse Biosciences

A

Alec Salvino

Parse Biosciences

A

Ajay Sapre

Parse Biosciences

I

Ian Dowsett

Parse Biosciences

Z

Zeynep Sayar

Parse Biosciences

A

Alex Koriath

Parse Biosciences

A

Alex Sova

Parse Biosciences

J

Jason Siputro

Parse Biosciences

G

Gary Geiss

Parse Biosciences

C

Charles Roco

Parse Biosciences

A

Alex Rosenberg

Department of Anaesthesia and Critical Care, Royal Brompton & Harefield Hospitals, Guy’s and St Thomas’ National Health Service Foundation Trust, London, United Kingdom (A.R., C.V.).